Giuliana Pomponio, et al.. Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems.. Toxicology Letters, Elsevier, 2015, 233 (2) roughly corresponding to the human therapeutic plasma concentration. Our results showed that IBU 40 uptake was rapid and a dynamic equilibrium was reached within 1 or 2 days. All three cell systems 41 efficiently metabolised IBU. In terms of species-differences, our data mirrored known in vivo results. 
The stability of IBU in both aqueous solutions and in DMSO (the vehicle used to prepare stock 244 solutions), was checked in preliminary assays, mimicking the actual experimental conditions. Distilled 245 water, culture media and IBU solutions in DMSO were kept at 37°C for different incubation times in 246 glass lab-wear and plastic tubes and analysed by HPLC. 247
Cross-contamination among wells 248
In the adjacent wells to those containing IBU at the applied concentrations, a corresponding amount of 249 DMSO (vehicle control) was added. At the end of the experiment, the content of these control wells 250 was stored at -80°C until HPLC analysis. The IBU content in these control wells served as an 251 indication of possible contamination across wells due to IBU evaporation. 252
Adsorption to plastic devices 253
In order to measure adsorption to the plastic, once the content of each well was removed, the wells 254 were washed twice with PBS before adding 2 mL methanol. The plate was sealed with Parafilm, and 255 kept on a horizontal shaker (350 rpm) at room temperature for 2 h before transferring the complete 256 volume into a LoBind tube. 257
Sequestration by the matrix 258
To determine the amount of IBU possibly sequestered by proteins in the collagen or Geltrex™ matrix 259 used for PRH and PHH SW cultures, repeated exposure experiments were conducted with the same 260 schedule of the main experiment but in the absence of cells ('blank experiment'). Here, corresponding 261 volumes of collagen I (PRH) and Geltrex™ (PHH) were exposed to high and low IBU concentrations 262 or DMSO vehicle control. Sampling was performed on the first (0/1) and last (13/14) day of treatment, 263 at two time points (2 min and 24 h). 264
Assessment of cell viability after IBU exposure 265
Preliminary experiments were performed to determine the cytotoxicity of IBU. For all applied assays, 266 the results were expressed as a percentage versus the vehicle treated control. 267
In PRH, the dose finding was performed in three stages (Table 2) , starting with treatment with a broad 268 concentration range in 96-well plate ML culture for 24 h. After the pre-screen, three biological 269 12 replicates in 24-well plate SW culture were treated for 1, 3 and 14 days to assess a preliminary TC 10 270 (the concentration causing 10% cytotoxicity, in the specific case measured as ATP depletion). Finally, 271 three concentrations around the determined TC 10 were tested in 6-well plate SW cultures, the format 272 for the final experiments, for 14 days repeated exposure. 273
The cell viability was determined via ATP levels that were measured using the CellTiter-Glo® 274 Luminescent Cell Viability Assay (Promega®) according to the manufacturer's protocol including slight 275 modifications. Briefly, after the corresponding exposure time cell cultures in 96-, 24-or 6-well plates 276
were incubated with 100 µL, 600 µL or 900 µL CellTiter-Glo® Reagent for 2 min on an orbital shaker. 277
After 10 min the luminescence signal was measured. 278
In PHH, preliminary assessment of IBU cytotoxicity was performed in one culture (donor S0302V, not 279 further used for kinetic testing): 0.05 x 10 6 viable cells were seeded onto collagen I coated 96-well 280
Biocoat® plates (Dutscher, France) in Williams' E medium supplemented with 10% FBS, 4 µg/mL 281 insulin, 1 µM dexamethasone and 50 µg/mL gentamycin. Following an overnight incubation, the cell 282 monolayer was covered with 350 µg/mL Geltrex™ in culture medium without FBS for 24 h. Six IBU 283 concentrations were tested, corresponding to the concentrations applied to PRH in 24-well SW 284 cultures (see Table 2 ). A MTT test was performed after 1, 3 and 14 days of treatment. Here, cells were 285 incubated with 1 mg/mL thiazolyl blue tetrazolium bromide for 30 min, the supernatant was replaced 286 by 100 µL DMSO per well. After gentle shaking, the absorbance was measured at 595 nm. 287
For IBU cytotoxicity determinations, 2.5 x 10 5 HepaRG cells were seeded per well in 96-well plates as 288 described previously (Aninat et al., 2006) . Briefly, after 1, 3 and 14 days of treatment, medium was 289 removed and serum-free medium containing MTT (0.5 mg/mL) was added to each well and incubated 290 for 2 h at 37°C. After removal of the incubation solution, water-insoluble formazan was dissolved in 291 DMSO and absorbance was measured at 540 nm. 292
IBU exposure for kinetic experiments 293
On the basis of results obtained from the preliminary cytotoxicity tests, the two IBU concentrations 294 used during the kinetic experiments in the three cell culture systems were set as follows: the TC 10 in 295 13 the corresponding hepatic system, to reveal underlying mechanisms of toxicity, without causing a 296 significant decrease in the number of cells; 1/10 TC 10 , which should give an insight into 297 pharmacological actions of the drug on cellular level. Eventually, the applied IBU treatment 298 concentrations were 10 µM and 100 µM in PRH and HepaRG cells, and 100 µM and 1000 µM in PHH. 299
Prior to each experiment IBU stock solutions (500-or 1000-fold) were prepared in DMSO and stored 300 at -20°C until needed. Treatment solutions were prepared by diluting the IBU stocks (50 mM and 5 301 mM for PRH and 500 mM and 50 mM for PHH) 1:500 in serum-free culture medium, keeping DMSO 302 concentration at 0.2%. The stock solutions (100 mM and 10 mM) for the HepaRG cells were diluted 303
(1:1000) in medium containing 1% DMSO and 2% FBS to obtain ready-to-use solutions. Aliquots of 304 the daily treatment solution (considered as time 0 samples) and of the stock solutions were stored at -305 80°C until HPLC analysis. 306
Cell treatment with IBU TC 10 and 1/10 TC 10 was initiated by adding 1.5 mL (PRH) or 2 mL (PHH and 307
HepaRG cells) per well of the corresponding ready-to-use solutions or the vehicle (control wells). Per 308 definition, the day of the first exposure was referred to as day 0 and media were changed on a daily 309 basis for 14 days. 310
Sample preparation for HPLC analysis 311
A sample of cell culture media at time 0 min (t 0 ) to verify the actual IBU concentration added to the 312 well, and samples of supernatant and cell lysate were collected on day 0/1 and day 13/14 at 5 different 313 time points (TP): 2 min, 30 min, 1 h, 3 h and 24 h for PRH and PHH. In parallel, samples to measure 314 plastic adsorption were prepared on empty wells, as described above. The TP selection was based on 315 intrinsic characteristics of IBU (e.g. 90-99% protein binding, rapid metabolism with half-life 2-4 hours) 316 and the cell systems (e.g. metabolic competence). The a priori selected TP were confirmed in a 317 preliminary experiment for PRH and PHH, whereas for HepaRG cells uptake into the cells was 318 delayed. Therefore, to get a better description of the kinetic behaviour in HepaRG cells, the initially 319 selected TP were changed to 30 min, 1 h, 3 h, 6 h and 24 h . 320 14 At the selected TP, the supernatant was pipetted into LoBind tubes, and cells were washed twice with 321 PBS. The SW cultured PRH and PHH were scraped and transferred into a new LoBind tube; the well 322 was rinsed with 250 µL methanol, which was added to the same tube. Finally, the cell lysate was 323 homogenised using an in-probe sonicator and the volume was adjusted with methanol to 1 mL. 324
HepaRG cells were scraped in 200 µL PBS and transferred into a new LoBind tube containing 600 µL 325
Methanol. A volume of 200 µL PBS was used to wash the well and after adding it to the same tube, 326 the cell lysate was homogenised (in-probe sonication). All fractions were stored at -80°C until HPLC 327 analysis. 328
HPLC analysis of IBU 329
Methanol was selected as the extraction solvent after checking extraction efficiency: IBU recovery 330 from the 3 media and HepaRG cell lysate was > 95%; for PRH and PHH cell lysate for which the 331 recovery was ~75% an appropriate correction factor was applied for the calculation of IBU content. 332
Three times volumes methanol were added to the supernatant collected at t 0 and at different TP; the 333 mixture was vortexed for 30 s. All samples, including cell lysates, were centrifuged (Eppendorf 5417R; 334 5 min, 4°C, 2500 rpm); the upper phase was transferred into amber glass vials for HPLC analysis. No adsorption to plastic vial walls was included, as the obtained experimental data with the three 364 models showed that none occurred for IBU or that it was negligible. Due to sequestration by collagen, 365 for PRH the "multiple binding" processes to medium proteins, collagen walls were modelled as a 366 single process. For PHH and HepaRG cells there was no evidence of non-specific binding from the 367 blank experiments, thus it was neglected.. 368
Since the experimental data showed that IBU can be metabolised within cells, biotransformation was 369
accounted for in the model. The following three differential equations correspond to the general form 370 of that model: 371
where N cell is the number of cells in the assay system, C cell and C med the concentration of IBU in the 375 cells and medium respectively, V cell and V med the volumes of a cells and of the medium respectively, F in 376 and F out the entry and exit rate flows for one cell respectively, k 1 and k 2 the rate constants for binding 377 and unbinding to medium proteins, respectively. 378
where V max is maximal rate of metabolism and K m the metabolism Michaelis-Menten constant. In Eq. 5 381 a cell volume proportionality difference was used in the definition of K m rather than concentrations, 382 with no change in the results. The cell volume used for the conversion was 6700 μm 3 for 383 PRH(experimentally determined in-house) and 3400 μm 3 for PHH and HepaRG cells (2000) . Details of 384 the parameters used for the modelling are given in Tables S1 and S2 (Supplementary material) . 385
For each model the best fit for exchange rates were used: For PRH, the best fit was obtained using 386 first order rates for collagen binding and unbinding, cell entry and exit rate and metabolism (the range 387 of concentration assayed did not include doses high enough to identify a maximum rate of 388 metabolism). For PRH model Eq. 5 above was therefore replaced by its first order equivalent: 389
For PHH, no binding to GelTrex™ was observed and its rate was set to zero, first order cell entry and 392 exit rate and saturable metabolism gave the best fit. 
18 parameter values were supposed to vary following predefined non-uniform distributions. We used log 418 normal distributions. For example, in the case of PHH the cell entry flow rate was supposed to vary log 419 normally around a "population" mean (unknown, to be estimated together with the individual values) 420 with an estimated "population" geometric variance. In the end, a set of parameters was obtained for 421 each individual culture, one set of "population" averages and one set of "population" variances. The 422 (geometric) population means themselves were specified with the prior distributions given in Table 5 . 423
The (geometric) population variances were assigned half-normal prior distributions. In blank experiments, results showed that collagen I (used with PRH) sequestered IBU in a time-and 449 concentration-dependent manner (Table 3) . IBU levels in collagen increased on d0 up to 15% after 24 450 h. On d13, the percentages levelled off at around 30% at each time point and concentration, 451 suggesting a saturation of the extracellular matrix. A fraction of the added concentration (content of t 0 452 media) of 15 and 30%, on d0 and d13, respectively, were factored into the intracellular IBU 453
concentrations. Amounts <5% of the nominal concentrations were within the experimental variance 454 and hence were not taken into consideration, also in view of the absence of cells, which are thought to 455 compete with collagen. 456
Analyses of Geltrex™ preparations (used with PHH) showed that negligible binding of IBU to the 457 matrix molecules was found even after repeated exposure with 1000 µM. In accordance with these 458 findings, IBU detected in the corresponding supernatants was in the range 95-108%. 459 460
Kinetic profile of IBU in PRH 461
The analyses of cell culture media at t 0 revealed that a mean of 8.7 ± 0.7 µM and 85.3 ± 10.3 µM were 462 applied vs. a nominal concentrations of 10 µM and 100 µM, respectively, with a CV of 8-12% (N = 20 463 per concentration). 464
At 10 µM (low concentration) a similar IBU kinetic profile was observed on d0 and d13 both for the cell 465 lysate and the supernatant compartments (Figure 2, A and B) , indicating that the repeated treatment 466 did not result in any saturation, inhibition or induction phenomena. A rapid and progressive 467 intracellular uptake of IBU was evident from 2 min to 1 h. After a steady state from 1 to 3 h the amount 468 20 of IBU in the cell lysates decreased up to 24 h (Figure 2, A) . In parallel, a non-proportional decrease 469 was observed over time in the supernatant, indicating a steady state from 1 to 3 h followed by a drop 470 to 3 and 12% of applied IBU at 24 h of d0 and d13, respectively (Figure 2, B) . The non-quantitative 471 correspondence between the decrease in the supernatants and the increase in the cell lysates over 472 time was confirmed by the calculation of the mass balance (Figure 2, C) , that is the total amount of 473 IBU recovered in all the different compartments at a given time point, compared to the initially added 474 amount. It indicated a "apparent" loss of IBU over time (striped bars in Figure 2 , C), which could be 475 attributed to biotransformation processes (slightly lower on d13). 476
At 100 µM IBU (high concentration), the kinetic profile was similar (Figure 2 , D and E): the low to high 477 concentration ratio (1/10) was maintained in the IBU amount measured in cell lysates, increasing on 478 both days from 2 min to 1 h. A steady state (1 to 3 h) followed and then a decrease to a minimum of 479 ~6 and 13% at 24 h (d0 and d13, respectively) (Figure 2, D) . 480 
Kinetic profile of IBU in PHH 486
When the kinetic profile of IBU was followed in PHH, the different human donors were firstly evaluated 487 individually rather than as biological replicates, due to high intra-individual variability. Although the 488 absolute values were different, representing the expected variability among individuals, analysed 489 donors exhibited a comparable trend: on this basis, distinct donors were handled as biological 490
replicates. 491
This high variability (translated in high SD bars) was very likely attributed to differences in metabolism, 492 although the hepatic pathology of the donors might also have contributed. In order to characterise the 493 competence of PHH to metabolise IBU, some CYP specific activities were measured in PHH from 494 21 each donor (Table 4) . Of particular interest was CYP2C9, which is the main CYP involved in IBU 495 metabolism. PHH from Donor B1032 were expected to show a low level of oxidative IBU metabolism. 496 Indeed, after 3 days of repeated exposure, a high degree of cytotoxicity was observed at both 497 concentrations. As a result, the experiment with PHH from Donor B1032 was stopped because it did 498 not meet the criteria set in the experimental design, i.e. high concentration corresponding to TC 10 , thus 499 assuming a nearly constant number of cells throughout the experimental treatment. As a 500 consequence, biokinetic data reported on d13 included only samples from PHH from the Donors 501 S1045 and B1050. 502
The mean IBU concentration at T 0 was 97.8 ± 10.0 µM and 803.7 ± 78.6 µM vs the nominal 100 µM 503 and 1000 µM, respectively, with a CV of 2-20%% with N = 20 (for each concentration). 504
At 100 µM (low concentration) no differences in IBU kinetic profile were evident between d0 and d13. 505 IBU uptake by PHH was very rapid, reaching maximum values (5% of the applied concentration) after 506 2 min at d0 and after 30 min at d13 (Figure 3, A) . Subsequently, a steady state up to 3 h was followed 507 by a decrease to a minimum of ~ 1% at 24 h. IBU content in the PHH supernatant samples showed an 508 almost continuous decrease over time with a less pronounced steady-state at early times. In no case 509 the intracellular amount and the decrease in the supernatant were quantitatively correlated (Figure 3,  510 B). The sum of the amount of IBU found in the cell lysates plus supernatants declined quite rapidly 511 starting from the first time point on d0 ( Figure 3, C) ; on d13 the decreasing rate was slower, but after 512 24 h in both cases very low IBU values were attained (10.2 ± 4.8% on d0 and 8.6 ± 4.3% on d13). As 513 evidenced by the relative IBU distribution in the different compartments (Figure 3, C) , IBU content in 514 the cell lysate never exceeded 5%, the amount measured at the steady state, supporting the 515 occurrence of a very efficient metabolism of the parent compound by PHH. 516
The kinetic profile in the cell lysate over 24 h for the PHH treated with 1000 µM (high concentration; 517 Figure 3, D) showed a different pattern; the high/low intracellular concentration ratio was > 10 fold. 518
After a very rapid uptake into the cells, at 2 min the amount of IBU remained at a constant level 519 (around 1-3%) at d0; although very variable among donors, the trend was similar at d13. In contrast, 520 22 the supernatants revealed a slight decrease at earlier time points, (Figure 3, E) , then IBU levels were 521 almost constant up to 24 h. On d0 the relative distributions showed a decline in total recovered IBU 522 from cells plus supernatant (Figure 3, F) , but never below 50%. After repeated exposures, the 3 h time 523 point corresponded to very low recovery and nearly no variability between samples and donors, 524 contradicting results obtained both at previous time points as well as at 24 h, when results were 525 consistent with the overall kinetic behaviour were obtained. The data at 3 h were interpreted as a 526 technical problem, since at 24 h cell were perfectly viable and CYP2C9 activity was present (data not 527 shown), therefore the low metabolic capacity at 24 h cannot be attributed to cytotoxicity. Under these 528 conditions, the decrease in IBU mass balance was around 20-30% with most IBU recovered in the 529 supernatant at 24 h, as shown by its relative distribution (squared bars in Figure 3, F) . This suggested 530 a saturation of IBU biotransformation at 1000 µM, which could be expected at such a high 531 concentration. 532 533
Kinetic profile of IBU in HepaRG cells 534
The actual IBU mean concentration in the media at t 0 was 7.8 ± 1.2 µM and 85.4 ± 4.2 µM versus the 535 nominal 10 µM and 100 µM, with a CV between 5 and 16% with N = 20 (for each concentration). 536
In HepaRG cells treated with 10 µM IBU, the uptake started at 30 min, reaching a plateau after 3-6 h 537 (Figure 4, A) . In the supernatant a continuous decrease in IBU content was measured both on d0 and 538 d13, reaching a similar amount at 24 h (Figure 4, B) . The relative distribution showed a continuous 539 and constant decrease of IBU mass balance in the course of 24 h both on d0 and d13. Although the 540 reduction rate was higher after repeated exposure (Figure 4 , C), likely attributable to higher level of 541 CYP2C9 on d13. 542
After treatment of HepaRG cells with 100 µM IBU (high concentration), the measured kinetic profile 543 was similar: in the cell compartment on d0 and d13 IBU content remained low, under 0.5 nmol/well 544 (Figure 4, D) . A gradual decrease in IBU content was observed in the supernatants on d0 higher on 545 d13, but never quantitatively related to the increase in intracellular content (Figure 4, E) . The total IBU 546 23 recovery showed a continuous decrease over time on both days (Figure 4, F) , although significantly 547 lower on d13. This suggests a possible increase in the CYP2C9-related biotransformation capacity of 548 this cell model over time. The IBU amount in the supernatants was 10 fold higher than that measured 549 at 10 µM IBU, respecting the high/low concentration ratio, whereas it was < 10 in cell lysates. 550 551 3.5 Pharmacokinetic Modelling 552 Figure 5 shows the measured and modelled amount of IBU in the medium and cell lysates of PRH 553 cultures over the repeated treatment of 14 days. Since IBU was applied daily, the concentration was 554 reset to nominal medium concentrations every 24 h. It was assumed that IBU content in cell lysate 555 corresponds to intracellular concentrations; the assumption was nevertheless reasonable, since, 556 based on its low lipophilicity (log K OW = 0.8 at pH 7.4), IBU is unlikely sequestered within membranes. 557
The data were well matched by the model and fairly consistent across replicates. The various curves 558 were very similar, showing that there was reasonable uncertainty in the model predictions (the 559 estimate of residual uncertainty corresponded to a CV of 30%). 560
A dynamic equilibrium was reached already after the first day. The ratios Q cell over Q med were close to 561 0.2, but the total cellular volume was about a 1000th of the medium volume, so the ratio of 562 concentrations was about 200. As a result, cells had a 200 times higher IBU concentration than the 563 medium. 564
A similar model fitted for PHH data is shown in Figure 6 . The PHH from Donor B1032 proved to be 565 very sensitive to IBU toxicity at the applied concentration, thus only data from the first day were 566 obtained. Here, significant inter-individual variability was noted, thus a population approach was used 567 to analyse the data deriving from PHH. The fits were quite good, but uncertainty (reflected by the 568 spreading of the simulated curves) was as expected higher compared to PRH, resulting from 569 underlying measurement errors and modelling approximations (the estimate of residual CV being 570 40%). In two PHH donors, the intracellular quantity of IBU was noticeably higher than predicted. In the 571 data sets of PHH from Donors S1045 and B1050, a dynamic equilibrium was reached practically on 572 24 d1, as previously seen in the modelling of the PRH data. The IBU amounts in PHH of the 100 µM 573 group were underestimated by the model. This could be due to systematic error in IBU recovery, non-574 linearity in cellular uptake of efflux, lower metabolism at IBU low concentration, or some unknown 575 mechanism. More data would be required to identify the actual cause of this observation. 576
The data and model fit for HepaRG cells are given in Figure 7 . The applied model layout was similar to 577 that previously described for PRH and PHH. As for the PHH data, the three replicates were analysed 578 in a population framework, but reflecting inter-experiment variability instead of inter-individual 579 differences between donors. There was a rather large proportion of non-detectable levels in the low-580 dose experiments with substantial uncertainty (residual uncertainty: CV = 45%). Furthermore, an 581 underestimation of some data points at 10 µM concentration in cell lysates was observed as 582 previously observed for the PHH. These results seem however, globally consistent with those of the 583 other two culture systems. For both PHH and HepaRG cells, the ratios Q cell over Q med were close to 584 0.01, indicating that those cells had only a 10 times higher IBU concentration compared to the medium 585 -that is much less than in PRH, likely due to more efficient metabolism. 586
The posterior parameter distributions obtained after MCMC sampling for the "average" parameters are 587 summarised in Table 5 . They characterise the kinetic behaviour observed an average experiment for 588 PRH or HepaRG cells, or of the cells of an average donor in PHH. Given the dose assayed in the 589 various systems and the cell capabilities, we could estimate a maximum rate of metabolism only in 590 PHH. The low-dose metabolic clearances, V max / K m , could be estimated in all systems with very good 591 precision in PRH (5% CV) and less so in PHH and HepaRG (50% CV). The PRH have clearly lower 592 clearance rates, which explained the much higher IBU concentrations observed in those cells. 593
Clearance rates were similar for the different human cells, given the significant variability between 594 donors and experiments. In HepaRG cells, metabolic clearance is known to increase with time, and 595 we estimated (slope parameter α) that it was about 60% higher after 14 days compared to the start 596 (Table 5) . 597 As the first step we checked factors possibly affecting the bioavailability of IBU under the experimental 621 conditions used, and showed that IBU was readily soluble and chemically stable, neither cross-622 contamination among wells nor adsorption to plastic devices occurred. The use of FBS or albumin in 623 the medium was reduced to a minimum, i.e. not affecting IBU recovery or total bioavailability. 624 26 Furthermore, no IBU was physically sequestered into the Geltrex™ used in PHH SW culture. By 625 contrast, we found a time-and concentration-dependent amount of IBU in collagen I used in PRH 626
cultures. This finding was relevant because physically sequestered IBU could be assumed as 627 intracellular content, and erroneously interpreted as bioaccumulation. 628
The study design was similar to that of the in vivo kinetic testing (OECD Test Guideline 417). The 629 comparison of kinetic behaviour obtained between single and repeated treatments allowed the study 630 of inhibition, saturation or induction of cellular influx/efflux, metabolism and bioaccumulation 631 processes. 632
The used 100 µM IBU corresponds to 20.6 µg/mL, which approximates the recently reported human 633 peak plasma concentration (C max = 22.6 ± 5.6 µg/mL) measured upon oral intake of 400 mg IBU 634 (Vilenchik et al., 2012) in the low range of therapeutic doses. Hence, the cross-model comparison of 635 the three hepatic systems was conducted at 100 µM IBU. 636
The obtained modelled results showed a coherent picture for IBU in vitro biokinetics across the three 637 models: (i) IBU quickly entered cells; (ii) after multiple exposures a dynamic equilibrium was reached 638 within one or two days; (iii) the decrease in the medium was not quantitatively related to the increase 639 in the cell lysate fractions. All three models showed a significant capacity in metabolising IBU; 640 therefore, cells removed (by biotransformation) the parent compound in 24 h, resulting in no 641 bioaccumulation after daily treatment for 14 days This is in line with information from in vivo 642 pharmacokinetic data in humans showing that 60% of a given dose was excreted within the first 24 h 643 (Adams et al., 1969) . Although the experimental data were available only on d0 and d13, modelling 644 allowed the prediction of the daily kinetic behaviour along the treatment period. 645
The uptake of IBU was likely due to passive transport through the cell membrane, being very rapid 646 and not saturable: and assumed to be a "first order" kinetic process. Our assumption was supported 647 by experiments conducted on Caco2 cells indicating a passive transport (data not shown) and by data 648
showing that in rats IBU is an Oatp1a1 inhibitor (Zhang et al., 2013) 
